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• MDNA55 consists of a bioengineered circularly permuted IL-4 (cpIL-4) fused to 
the catalytic domain of Pseudomonas exotoxin A (PE).3
• MDNA55 binds to IL-4 receptor (IL-4R) overexpressed by GBM and 
immunosuppressive cells of the tumor microenvironment.4-7
• This results in internalization of MDNA55 in the target cells where protease-
mediated cleavage of the pro-apoptotic domain of MDNA55 (i.e. PE) results in 
cell death by arresting protein synthesis.8
MDNA55:  TARGETING THE INTERLEUKIN-4 RECEPTOR
Figure 1: Schematic representation of 
MDNA55 mechanism of action
MDNA55: A Molecular Trojan Horse
MDNA55-05 PHASE 2 STUDY DESIGN
An open-label, non-randomized, Phase 2, multicenter study of Convection-
Enhanced Delivery (CED) of MDNA55 in adults with recurrent or progressive
Glioblastoma (n=52) ClinicalTrials.gov ID#: NCT02858895
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• Patient Safety 
• Tumor Response 
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METHODS:
BACKGROUND
• Treatment options for patients with recurrent GBM are very limited and positive 
outcomes remain very rare.1,2
• Tumor-targeted therapies for recurrent GBM has been limited by suboptimal 
delivery of therapeutic agents. 
• Intratumoral delivery of MDNA55 using MRI-guided convection enhanced 
delivery (CED) is currently being tested in a Phase 2 open label study in 
patients with recurrent GBM (NCT02858895).
• MDNA55 is co-infused with Gadolinium-based contrast agent (GdDTPA) to 
allow real-time monitoring of drug distribution and to optimize intratumoral 
catheter placement.
Table 2.  Subjects receiving adaptive infusion volumes based on tumor size (n=12)
Vol of enhancing 
mass (cm3)
Vol of infusion
(mL)
Vol of distribution
(mL)
% Coverage
Enhancing lesion
Mean 
(stdev) 
8.2
(7.5)
32.7
(18.3)
66.4
(29.8)
74.7%
(16.9)
Median
(range)
5.3
(1.6 – 25.5)
27.0
(12.0 – 66.0)
58.9
(30.4 – 130.2)
77.2
(46.0 – 94.3)
Evaluation of drug distribution patterns and safety data suggested that improvements
to drug distribution could be further enhanced by moving to a fixed volume of 60 mL
administered via 4 catheters and allowing placement outside the peritumoral area.
(Table 1, Group 2).
SAFETY OF MDNA55
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Figure 2. Percent coverage of enhancing lesion (left Y-axis) and volume of distribution (right Y-axis) versus 
volume of infusion; SD = Standard Deviation
• No systemic toxicity following doses of 18 – 240 μg of MDNA55.
• No clinically significant laboratory abnormalities.
• Drug-related adverse events were primarily neurological/aggravation of pre-
existing neurological deficits characteristic with GBM.
Table 3.  Subjects receiving fixed infusion volume of 60 mL (n=11)
Vol of enhancing 
mass (cm3)
Vol of infusion 
(mL)
Vol of distribution
(mL)
% Coverage
Enhancing lesion
Mean 
(stdev) 
8.3
(4.5)
59.6
(0.9)
103.1
(43.6)
59.9%
(23.1)
Median
(range)
6.8
(4.0 – 16.9)
60.0
(57.6 – 60.3)
76.3 
(58.4 – 175.3)
63.1%
(21.9 – 97.2)
To date, 39 subjects have been enrolled in this clinical trial. Preliminary results of
MDNA55 distribution are available for 23 subjects. Total volume of MDNA55 was initially
administered to subjects based on tumor size (Table 1, Group 1).
• Realtime imaging with co-infused GdDTPA distribution enables optimization of
catheter placement and infusion parameters.
• Infusion volumes exceeding 40 mL and placement of catheters outside the
enhancing tumor did not improve the target percentage coverage of the tumor
and may contribute to increased safety events.
• Under the current protocol version, all subjects are receiving individualized
volume of MDNA55 (according to tumor size), but not exceeding 40 mL to
minimize risks of target effects.
• There is early evidence of sustained disease control and biologic activity of
MDNA55.
• Further refinement of MDNA55 regime can enhance patient benefits.
This Research is Partly Supported by a Product Development Grant from Cancer 
Prevention and Research Institute of Texas (CPRIT) awarded to Medicenna 
BioPharma, Houston, TX
Parameters Group 1 Group 2
Drug Conc. 1.5 µg/mL 1.5 - 3.0 µg/mL
Vol of Infusion Based on tumor size Fixed (60 mL)
Tracer / conc. Gadolinium; 7mmol Gadolinium; 7mmol (then 2mmol*)
Flow rate Up to 50 µL/min/catheter
Total flow rate of all catheters does 
not exceed 50 μL/min
# Catheters / 
Placement
1 - 4 catheters in tumor 
region
4 catheters, if possible
(min of 2 catheters in tumor region 
and remaining catheters within 2 cm 
of peritumoral margin)
Real-Time Infusion 
Monitoring
First 3 - 6 hours of infusion
Total Infusion Time Up to 48 hours
Catheter trajectory planning and infusate distribution was performed using Brainlab
iPlan® Flow software. Percent coverage was calculated based on the fraction of the
target volumes covered by the determined gadolinium distribution at end of infusion
(example shown below).
Tumor Volume – 4.7 cm3
Tumor Diameter – 2.3 cm3
Vi – 60 cm3
Vd of Gad – 95 cm3
Vd/Vi ratio - 1.6
Tumor Coverage – 95%
*Concentration of gadolinium was reduced to 2 mmol in later versions of the protocol due to FDA and 
EMA recommendation to minimize exposure in humans.
Although increased infusion volumes (exceeding 40 mL) led to increased mean volume 
of distribution, it did not improve the target percentage coverage of the enhancing 
lesion (Table 3, Fig 2). 
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EFFICACY OF MDNA55: PATTERNS OF RESPONSE
Case 1: Subject experienced increase in contrast enhancement lasting over 120 days, due
to pseudo-progresssion, the result of local tissue reaction to inflammatory infiltration seen
with immunotherapies. Over the following 8 months, subject experienced continual tumor
decline eventually reaching to below baseline.
Case 2: Early onset response. Subject with a partial response (PR); tumor continued to
decline significantly after MDNA55 treatment in the absence of any pseudo-progression.
Subject is still ongoing on trial.
AEs ≥ Grade 3
Worst CTCAE Grade (n) Relatednessa SAE
Grade 4 Grade 3
I = Infusion 
D = Drug
Y = Yes
N = No
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
Peritumoral edema 1 I Y
Nervous System Disorders
Seizure 2 D / D Y / N
Hemiparesis 2 D, I / D, I N / N
Hydrocephalusb 1 D, I Y
Hemiplegia 1 D Y
Stroke 1 I Y
Psychiatric Disorders
Depression 1 D, I N
SAE = Serious Adverse Event
a As per Investigator or Sponsor
b The SAE of Hydrocephalus was assessed to be unrelated to study drug and the infusion procedure by the sponsor due 
to temporal gap.
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RESULTS:
